Royce & Associates LP Makes New $1.66 Million Investment in OptimizeRx Co. (NASDAQ:OPRX)

Royce & Associates LP purchased a new position in shares of OptimizeRx Co. (NASDAQ:OPRXGet Rating) in the 1st quarter, Holdings Channel reports. The firm purchased 44,000 shares of the company’s stock, valued at approximately $1,659,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mutual of America Capital Management LLC purchased a new stake in shares of OptimizeRx in the fourth quarter valued at $151,000. Ensign Peak Advisors Inc purchased a new stake in shares of OptimizeRx in the fourth quarter valued at $217,000. Northern Trust Corp grew its position in shares of OptimizeRx by 5.7% in the fourth quarter. Northern Trust Corp now owns 278,974 shares of the company’s stock valued at $17,327,000 after purchasing an additional 14,925 shares during the period. ProShare Advisors LLC purchased a new stake in shares of OptimizeRx in the fourth quarter valued at $269,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of OptimizeRx in the fourth quarter valued at $9,012,000. Hedge funds and other institutional investors own 83.61% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on OPRX. Roth Capital lowered their price objective on OptimizeRx from $112.00 to $66.00 in a research report on Thursday, May 5th. Piper Sandler initiated coverage on OptimizeRx in a report on Friday, July 1st. They issued a “neutral” rating and a $29.00 target price on the stock. Royal Bank of Canada reduced their target price on OptimizeRx from $100.00 to $50.00 in a report on Thursday, May 5th. SVB Leerink initiated coverage on OptimizeRx in a report on Friday, July 15th. They issued an “outperform” rating and a $38.00 target price on the stock. Finally, B. Riley reduced their target price on OptimizeRx from $71.00 to $56.00 and set a “buy” rating on the stock in a report on Wednesday, July 20th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, OptimizeRx currently has a consensus rating of “Moderate Buy” and an average price target of $52.50.

OptimizeRx Price Performance

Shares of OPRX opened at $24.23 on Friday. The stock’s 50-day moving average is $26.53 and its two-hundred day moving average is $33.62. The stock has a market cap of $439.82 million, a PE ratio of -151.44 and a beta of 0.70. OptimizeRx Co. has a 12 month low of $20.10 and a 12 month high of $99.18.

OptimizeRx (NASDAQ:OPRXGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.10). The company had revenue of $13.73 million for the quarter, compared to analyst estimates of $13.78 million. OptimizeRx had a negative return on equity of 1.76% and a negative net margin of 4.30%. During the same quarter in the prior year, the firm earned ($0.01) EPS. On average, research analysts anticipate that OptimizeRx Co. will post -0.02 earnings per share for the current year.

OptimizeRx Company Profile

(Get Rating)

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages.

See Also

Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRXGet Rating).

Institutional Ownership by Quarter for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.